Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the glial-fibrotic scar microenvironment after spinal cord injury: From integrated protection to systematic regulation of regenerative balance.

Journal of orthopaedic translation·2026
Same author

Effect of mitochondrial dysfunction on scar formation after spinal cord injury.

Frontiers in neurology·2026
Same author

Critical Appraisal of a Systematic Review Comparing Surgical and Conservative Therapies in Treating Meniscus Root Tears.

Kansas journal of medicine·2026
Same author

Lesion formation and impedance dependence of v-HPSD ablation (QDOT-MICROâ„¢) versus conventional power-control (SmartTouchâ„¢ SF): a head-to-head comparison in an ex vivo porcine model.

BMC cardiovascular disorders·2026
Same author

Blood-spinal cord barrier disruption after spinal cord injury: a time-dependent mechanistic review.

Frontiers in cellular neuroscience·2026
Same author

IL-3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Related Experiment Video

Updated: May 16, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Progression of human osteosarcoma with altered ANT1/SLC25a4 expression.

Shang-You Yang1, Riley Drees2, Bin Ning3

  • 1The University of Kansas School of Medicine-Wichita, Wichita, Kansas, Department of Orthopaedics.

Kansas Journal of Medicine
|May 15, 2026
PubMed
Summary

Adenosine nucleotide translocator 1 (ANT1/SLC25A4) is often reduced in osteosarcoma. Restoring ANT1/SLC25A4 expression in cells suppressed tumor growth, migration, and invasion, suggesting its role as a tumor suppressor.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 16, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma (OS) is a primary bone cancer common in children and adolescents.
  • Bioinformatics identified Adenosine nucleotide translocator 1 (ANT1), encoded by SLC25A4, as potentially involved in OS development and progression.

Purpose of the Study:

  • To investigate the expression levels of ANT1/SLC25A4 in clinical osteosarcoma specimens and cell lines.
  • To evaluate the potential of ANT1/SLC25A4 as a prognostic biomarker for osteosarcoma.
  • To elucidate the mechanistic role of ANT1/SLC25A4 in osteosarcoma pathogenesis.

Main Methods:

  • Immunohistochemical (IHC) analysis of ANT1 expression in 63 human OS tissue sections.
  • Genetic modification of OS cell lines (MG-63, HOS) for SLC25A4 overexpression or knockdown.
  • In vitro assays (proliferation, scratch wound-healing, transwell invasion) to assess cellular behavior.
  • Statistical analysis including ANOVA and bivariate correlation.

Main Results:

  • Diminished ANT1 expression was observed in the majority of clinical OS specimens (48/63) compared to normal periosteal tissue.
  • SLC25A4 knockdown in vitro significantly increased osteosarcoma cell proliferation.
  • Conversely, SLC25A4 overexpression significantly inhibited osteosarcoma cell migration and invasion (p <0.05).

Conclusions:

  • ANT1/SLC25A4 is frequently downregulated in clinical osteosarcoma.
  • Restoration of ANT1/SLC25A4 suppresses aggressive cellular phenotypes in vitro, suggesting a tumor suppressor role.
  • Further research is warranted to correlate SLC25A4 expression with patient survival and understand its molecular pathways in OS.